Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2019-09-09 Share Issue/Capital Cha…
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
Bone Therapeutics SA: Information on the total number of voting rights and shares
Share Issue/Capital Change Classification · 99% confidence The document is dated September 9, 2019, and announces an increase in the total number of voting rights and shares due to the conversion of convertible bonds. It explicitly states that the information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the publication of major shareholdings. The core content is a mandatory disclosure detailing the change in the total number of shares with voting rights (the denominator) and the potential number of shares that could be created upon exercise of warrants and conversion of bonds. This type of mandatory disclosure regarding changes in the total share count and voting rights, often triggered by capital structure events like bond conversion, aligns best with filings related to capital structure changes or major shareholding notifications. Since it details the change in the total number of shares/voting rights (the denominator) following a capital event (bond conversion), it is most closely related to 'Share Issue/Capital Change' (SHA) or 'Major Shareholding Notification' (MRQ). Given the focus on the total number of voting rights and the calculation of the denominator following a capital event, SHA is a strong fit, but MRQ specifically covers notifications of changes in significant share ownership levels, which often includes the total voting rights disclosure. However, the document is fundamentally about the change in the total share capital and voting rights base due to a financing event (bond conversion). The category 'Share Issue/Capital Change' (SHA) covers updates on company fundraising, financing activities, or capital structure changes. This announcement is a direct consequence of a financing activity (bond conversion) impacting the capital structure. It is not a general earnings release (ER) or a comprehensive quarterly report (IR). It is a specific regulatory disclosure about the capital base.
2019-09-09 English
PR_2019-09-09_BT_CB Denominator_EN_Final.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is dated September 9, 2019, and is titled "Information on the total number of voting rights and shares." It explicitly states that the information is published in accordance with Article 15 of the Belgian Law regarding the publication of major shareholdings. The core content details changes in the total number of shares, voting rights, outstanding convertible bonds, and warrants due to a recent issuance. This type of mandatory disclosure regarding changes in the capital structure and voting rights denominator is best classified as a notification related to share capital changes or major shareholding changes. Given the specific focus on the total number of voting rights (the denominator) resulting from capital events (bond conversion), it aligns closely with 'Share Issue/Capital Change' (SHA) or potentially 'Major Shareholding Notification' (MRQ). Since the announcement is triggered by the issuance of new shares following bond conversion, SHA is the most precise fit for reporting the resulting change in the total share count and voting rights denominator. It is not a full financial report (10-K, IR) or a general announcement of a report (RPA).
2019-09-09 English
PR_2019-09-09_BT_CB Denominator_FR_Final.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions" (Information relating to the total number of voting rights and shares) and explicitly states it is published in accordance with Belgian law regarding the declaration of significant shareholdings. It details changes in the total capital social, the number of voting shares, and potential shares after dilution due to the conversion of convertible bonds and the exercise of warrants. This content directly relates to changes in the company's share capital structure and ownership notification, which aligns best with the 'Share Issue/Capital Change' (SHA) category, as it reports the resulting share count after a capital event (conversion of debt to equity). It is not a general regulatory filing (RNS) because it is highly specific to capital structure changes.
2019-09-09 French
Bone Therapeutics publie ses résultats du premier semestre 2019
Earnings Release Classification · 96% confidence The document is a press release from Bone Therapeutics dated August 30, 2019, announcing its operational and financial results for the first half of 2019. It contains key highlights, financial figures (revenue, operating loss, cash position), and future outlooks. While it mentions that the full semi-annual report is available on their website, the document itself serves as the initial announcement of these results, which fits the definition of an Earnings Release (ER). H1 2019
2019-08-30 French
Bone Therapeutics publie ses résultats du premier semestre 2019
Earnings Release Classification · 96% confidence The document is a press release from Bone Therapeutics dated August 30, 2019, announcing its operational and financial results for the first half of 2019. It contains key highlights, financial figures (revenue, operating loss, cash position), and future outlooks. While it mentions that the full semi-annual report is available on their website, the document itself serves as the initial announcement of these results, which fits the definition of an Earnings Release (ER). H1 2019
2019-08-30 French
Bone Therapeutics publie ses résultats du premier semestre 2019
Earnings Release Classification · 96% confidence The document is a press release from Bone Therapeutics dated August 30, 2019, announcing its operational and financial results for the first half of 2019. It contains key highlights, financial figures (revenue, operating loss, cash position), and future outlooks. While it mentions that the full semi-annual report is available on their website, the document itself serves as the initial announcement of these results, which fits the definition of an Earnings Release (ER). H1 2019
2019-08-30 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.